[go: up one dir, main page]

GB2578008A - 1-Acetyl-5-Nitro-4-Phenyl-3-Pyrrolin-2-one for use in cancer treatment - Google Patents

1-Acetyl-5-Nitro-4-Phenyl-3-Pyrrolin-2-one for use in cancer treatment Download PDF

Info

Publication number
GB2578008A
GB2578008A GB1916084.5A GB201916084A GB2578008A GB 2578008 A GB2578008 A GB 2578008A GB 201916084 A GB201916084 A GB 201916084A GB 2578008 A GB2578008 A GB 2578008A
Authority
GB
United Kingdom
Prior art keywords
pyrrolin
acetyl
nitro
phenyl
mmp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
GB1916084.5A
Other versions
GB201916084D0 (en
GB2578008B (en
Inventor
Kuznecovs Jevgenijs
Veinbergs Grigorijs
Vorona Maksims
Domraceva Ilona
Kanepe-Lapsa Iveta
Leonciks Ainars
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Latvian Institute of Organic Synthesis
Original Assignee
Latvian Institute of Organic Synthesis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Latvian Institute of Organic Synthesis filed Critical Latvian Institute of Organic Synthesis
Publication of GB201916084D0 publication Critical patent/GB201916084D0/en
Publication of GB2578008A publication Critical patent/GB2578008A/en
Application granted granted Critical
Publication of GB2578008B publication Critical patent/GB2578008B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention relates to medicine, in particular to medical use of 1-acetyl-5-nitro-4- phenyl-3-pyrrolin-2-one exhibiting metalloproteinase and angiogenesis inhibiting properties for the treatment of cancer.

Claims (2)

Claims
1. Metalloproteinase (MMP) inhibitor l-acetyl-5-nitro-4-phenyl-3-pyrrolin-2- one (1) for use in the treatment of cancer accompanied by MMP over expression leading to the degradation of the extracellular matrix and to the development of metastasis.
2. MMP inhibitor according to Claim 1, wherein l-acetyl-5-nitro-4-phenyl-3- pyrrolin-2-one inhibits MMP-2 and MMP- 14.
GB1916084.5A 2017-07-24 2018-03-22 1-Acetyl-5-Nitro-4-Phenyl-3-Pyrrolin-2-one for use in cancer treatment Active GB2578008B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
LVP-17-51A LV15384B (en) 2017-07-24 2017-07-24 1-acetyl-5-nitro-4-phenyl-3-pyrrolin-2-one for use in the treatment of cancer
PCT/IB2018/051917 WO2019021067A1 (en) 2017-07-24 2018-03-22 1-acetyl-5-nitro-4-phenyl-3-pyrrolin-2-one for use in cancer treatment

Publications (3)

Publication Number Publication Date
GB201916084D0 GB201916084D0 (en) 2019-12-18
GB2578008A true GB2578008A (en) 2020-04-15
GB2578008B GB2578008B (en) 2022-03-16

Family

ID=59858757

Family Applications (1)

Application Number Title Priority Date Filing Date
GB1916084.5A Active GB2578008B (en) 2017-07-24 2018-03-22 1-Acetyl-5-Nitro-4-Phenyl-3-Pyrrolin-2-one for use in cancer treatment

Country Status (3)

Country Link
GB (1) GB2578008B (en)
LV (1) LV15384B (en)
WO (1) WO2019021067A1 (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004037171A2 (en) * 2002-10-18 2004-05-06 Merck & Co., Inc. Mitotic kinesin inhibitors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6500948B1 (en) 1995-12-08 2002-12-31 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors-compositions, uses preparation and intermediates thereof
JP2002504916A (en) 1997-06-21 2002-02-12 ロシュ ダイアグノスティクス ゲゼルシャフト ミット ベシュレンクテル ハフツング Barbituric acid derivatives with antimetastatic and antitumor activity
WO2006008303A1 (en) 2004-07-21 2006-01-26 Applied Research Systems Ars Holding N.V. Octahydropyrrolo[2, 3, c]pyridine derivatives and pharmaceutical use thereof
KR100829257B1 (en) 2006-06-22 2008-05-14 부경대학교 산학협력단 Carboxylic Glucosamine Compounds Inhibiting the Expression and Activity of Matrix Metalloproteinase-9 in Human Fibrosarcoma Cells and Matrix Metalloproteinase-9 Inhibitors Containing it

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004037171A2 (en) * 2002-10-18 2004-05-06 Merck & Co., Inc. Mitotic kinesin inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CHENG X C ET AL, "Design, synthesis and preliminary evaluation of novel pyrrolidine derivatives as matrix metalloproteinase inhibitors", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, vol. 43, no. 10, doi:10.1016/J.EJMECH.2007.12.020, ISSN 0223-5234, (20081001), Abstract, introduction; table 1 *

Also Published As

Publication number Publication date
GB201916084D0 (en) 2019-12-18
LV15384A (en) 2019-02-20
GB2578008B (en) 2022-03-16
WO2019021067A1 (en) 2019-01-31
LV15384B (en) 2019-05-20

Similar Documents

Publication Publication Date Title
CL2021001292A1 (en) Combination therapy including a krasg12c inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
JOP20220008A1 (en) Parp1 inhibitors
MY210070A (en) Heterocyclic compounds as immunomodulators
PH12023550161A1 (en) Pharmaceutical composition and use thereof
MX2021001186A (en) Purinones as ubiquitin-specific protease 1 inhibitors.
EP4292650A3 (en) Heterocyclic compounds as immunomodulators
GEAP202215303A (en) Chromane monobactam compounds for the treatment of bacterial infections
AU2018347307A1 (en) Heterocyclic compounds and uses thereof
BR112016019592A8 (en) COMPOUND, USE OF A COMPOUND, AND, PHARMACEUTICAL COMPOSITION
MX2022008478A (en) Low-dose brimonidine combinations and uses thereof.
NZ756307A (en) Formulations of cannabinoids for the treatment of acne
PH12021550122A1 (en) Solubilized apyrases, methods and use
MX2020012800A (en) Cannabinoids and uses thereof.
MY195210A (en) Imidazolone Compounds as Human Neutrophil Elastase Inhibitors
MX2019010218A (en) Pyrazole derivatives as bromodomain inhibitors.
MX2024003785A (en) CANCER ASSOCIATED IMMUNOSUPPRESSION INHIBITOR.
EA202192716A1 (en) COMPOSITION OF THE VAGINAL TABLETS
PH12020551331A1 (en) Treatment and prevention of pre-eclampsia
GEAP202115006A (en) Combination of bcl-2 inhibitor and mcl-1 inhibitor, uses and pharmaceutical compositions thereof
GB2578008A (en) 1-Acetyl-5-Nitro-4-Phenyl-3-Pyrrolin-2-one for use in cancer treatment
ZA201908446B (en) Combination of a mcl-1 inhibitor and a standard of care treatment for hematologic cancers, uses and pharmaceutical compositions thereof
WO2019040104A3 (en) Compounds, salts thereof and their use for the treatment of diseases
MY204443A (en) Pyridopyrimidinone derivatives for use as axl inhibitors
MX2021011610A (en) IADADEMSTAT COMBINATIONS FOR THERAPY AGAINST CANCER.
MX2018015240A (en) Compositions comprising timolol and their use in the treatment of rosacea by topical administration.